{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T00:16:59Z","timestamp":1783210619720,"version":"3.54.6"},"reference-count":209,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21975191"],"award-info":[{"award-number":["21975191"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52273110"],"award-info":[{"award-number":["52273110"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52372271"],"award-info":[{"award-number":["52372271"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2023III013GX"],"award-info":[{"award-number":["2023III013GX"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejphar.2026.178921","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:55:50Z","timestamp":1777647350000},"page":"178921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Insights into semaglutide cardiovascular research: Mechanisms, trials, and frontiers"],"prefix":"10.1016","volume":"1025","author":[{"given":"Jiexin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanbin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7125-7207","authenticated-orcid":false,"given":"Meng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taolei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.178921_bib1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7555\/JBR.38.20240387","article-title":"Molecular pathways in cardiovascular disease under hypoxia: mechanisms, biomarkers, and therapeutic targets","volume":"39","author":"Abdullaev","year":"2025","journal-title":"Journal of Biomedical Research"},{"key":"10.1016\/j.ejphar.2026.178921_bib2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2026.178921_bib3","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2026.178921_bib4","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13563","article-title":"Weight loss breaks the bond between nonalcoholic fatty liver disease and cardiovascular diseases: a clinical and epidemiological perspective","volume":"24","author":"Ala","year":"2023","journal-title":"Obes. Rev."},{"key":"10.1016\/j.ejphar.2026.178921_bib5","article-title":"445-P: network meta-analysis of seven glucagon-like Peptide-1 receptor agonists: a focus on cardiovascular outcome trials data","volume":"69","author":"Alfayez","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2026.178921_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/antiox13121454","article-title":"Oxidative stress in kidney injury and hypertension","volume":"13","author":"Arendshorst","year":"2024","journal-title":"Antioxidants"},{"key":"10.1016\/j.ejphar.2026.178921_bib7","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/cbf.3795","article-title":"The cardioprotective effect of human glucagon-like peptide-1 receptor agonist (semaglutide) on cisplatin-induced cardiotoxicity in rats: targeting mitochondrial functions, dynamics, biogenesis, and redox status pathways","volume":"41","author":"Atef","year":"2023","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.ejphar.2026.178921_bib8","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrm1666","article-title":"Autophagy: dual roles in life and death?","volume":"6","author":"Baehrecke","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2026.178921_bib9","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1053\/ajkd.2001.24522","article-title":"Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction","volume":"37","author":"Beattie","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2026.178921_bib10","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/14656566.2024.2343092","article-title":"A systematic review of the effect of semaglutide on lean mass: insights from clinical trials","volume":"25","author":"Bikou","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2026.178921_bib11","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","article-title":"Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial","volume":"67","author":"Bl\u00fcher","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2026.178921_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10741-024-10450-6","article-title":"GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction","volume":"30","author":"Bonfioli","year":"2025","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ejphar.2026.178921_bib13","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","article-title":"Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets","volume":"118","author":"Borlaug","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2026.178921_bib14","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41591-023-02526-x","article-title":"Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial","volume":"29","author":"Borlaug","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib15","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/eurheartj\/ehae775","article-title":"From cardiorenal to cardiovascular\u2013kidney\u2013metabolic syndromes","volume":"46","author":"Braunwald","year":"2024","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2026.178921_bib16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/414813a","article-title":"Biochemistry and molecular cell biology of diabetic complications","volume":"414","author":"Brownlee","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.178921_bib17","article-title":"Mechanism of absorption mediated by SNAC in an oral formulation of semaglutide","volume":"66","author":"Buckley","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2026.178921_bib18","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.jacc.2023.09.811","article-title":"Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction","volume":"82","author":"Butler","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2026.178921_bib19","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2026.178921_bib20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.rce.2020.06.005","article-title":"Medical treatment of type 2 diabetes mellitus: recommendations of the diabetes, obesity and nutrition group of the Spanish society of internal medicine","volume":"221","author":"Carrasco-S\u00e1nchez","year":"2021","journal-title":"Rev. Clin. Esp."},{"key":"10.1016\/j.ejphar.2026.178921_bib21","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1177\/15353702211013444","article-title":"Nicorandil inhibits TLR4\/MyD88\/NF-\u03baB\/NLRP3 signaling pathway to reduce pyroptosis in rats with myocardial infarction","volume":"246","author":"Chen","year":"2021","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.ejphar.2026.178921_bib22","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210518","article-title":"Ferroptosis in infection, inflammation, and immunity","volume":"218","author":"Chen","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/CM9.0000000000003230","article-title":"Oxidative stress in diabetes mellitus and its complications: from pathophysiology to therapeutic strategies","volume":"138","author":"Chen","year":"2025","journal-title":"Chin Med J (Engl)."},{"key":"10.1016\/j.ejphar.2026.178921_bib24","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/S0891-5849(00)00344-0","article-title":"The oxidative modification hypothesis of atherogenesis: an overview","volume":"28","author":"Chisolm","year":"2000","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib25","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/hrt.2006.088203","article-title":"Cell death in the cardiovascular system","volume":"93","author":"Clarke","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.ejphar.2026.178921_bib26","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib27","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the global burden of disease study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2026.178921_bib28","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S2213-8587(25)00092-0","article-title":"Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial","volume":"13","author":"Coskun","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejphar.2026.178921_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003198","article-title":"The global burden of disease attributable to high body mass index in 195 countries and territories, 1990-2017: an analysis of the global burden of disease study","volume":"17","author":"Dai","year":"2020","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib30","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jacc.2008.08.080","article-title":"Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease","volume":"53","author":"Damman","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2026.178921_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.101740","article-title":"An observational study of cardiovascular outcomes of tirzepatide vs glucagon-like Peptide-1 receptor agonists","volume":"4","author":"Dani","year":"2025","journal-title":"JACC Adv"},{"key":"10.1016\/j.ejphar.2026.178921_bib32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2213-8587(24)00304-8","article-title":"Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial","volume":"13","author":"Davies","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejphar.2026.178921_bib33","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2026.178921_bib34","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the american diabetes association (ADA) and kidney disease: improving global outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2026.178921_bib35","doi-asserted-by":"crossref","first-page":"v247","DOI":"10.1093\/eurheartjsupp\/suaf071","article-title":"ANMCO statement: semaglutide in the cardio-nephro-metabolic continuum","volume":"27","author":"De Luca","year":"2025","journal-title":"Eur. Heart J. Suppl."},{"key":"10.1016\/j.ejphar.2026.178921_bib36","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2026.178921_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071824","article-title":"Fibrosis, the bad actor in cardiorenal syndromes: mechanisms involved","volume":"10","author":"Delgado-Valero","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2026.178921_bib38","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2026.178921_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103244","article-title":"A detrimental role of endothelial S1PR2 in cardiac ischemia-reperfusion injury via modulating mitochondrial dysfunction, NLRP3 inflammasome activation, and pyroptosis","volume":"75","author":"Duan","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejphar.2026.178921_bib40","doi-asserted-by":"crossref","first-page":"436","DOI":"10.4103\/ijem.ijem_45_24","article-title":"Efficacy and safety of cagrilintide alone and in combination with semaglutide (Cagrisema) as anti-obesity medications: a systematic review and meta-analysis","volume":"28","author":"Dutta","year":"2024","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.ejphar.2026.178921_bib41","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.3727\/096368914X685582","article-title":"Intrarenal delivery of mesenchymal stem cells and endothelial progenitor cells attenuates hypertensive cardiomyopathy in experimental renovascular hypertension","volume":"24","author":"Eirin","year":"2015","journal-title":"Cell Transplant."},{"key":"10.1016\/j.ejphar.2026.178921_bib42","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s41669-021-00317-z","article-title":"Long-term cost effectiveness of oral semaglutide versus empagliflozin and Sitagliptin for the treatment of type 2 diabetes in the Swedish setting","volume":"6","author":"Eliasson","year":"2022","journal-title":"PharmacoEcon. Open"},{"key":"10.1016\/j.ejphar.2026.178921_bib43","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1007\/s12325-023-02750-4","article-title":"Risk of stroke in real-world US individuals with type 2 diabetes receiving semaglutide or a dipeptidyl peptidase 4 inhibitor","volume":"41","author":"Evans","year":"2024","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejphar.2026.178921_bib44","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1161\/CIRCRESAHA.120.316509","article-title":"Loss of cardiac ferritin H facilitates cardiomyopathy via Slc7a11-Mediated ferroptosis","volume":"127","author":"Fang","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2026.178921_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1226778","article-title":"Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China","volume":"14","author":"Feng","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178921_bib46","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1023\/A:1007735413477","article-title":"Apoptosis in cardiac diseases--new opportunities for novel therapeutics for heart diseases","volume":"13","author":"Feuerstein","year":"1999","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ejphar.2026.178921_bib47","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0008-6363(99)00372-7","article-title":"Apoptosis in cardiac diseases: stress- and mitogen-activated signaling pathways","volume":"45","author":"Feuerstein","year":"2000","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2026.178921_bib48","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12933-021-01412-5","article-title":"The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect","volume":"20","author":"Fisman","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2026.178921_bib49","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2026.178921_bib50","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1007\/s12325-022-02156-8","article-title":"The cost-effectiveness of oral semaglutide in Spain: a long-term health economic analysis based on the PIONEER clinical trials","volume":"39","author":"Franch-Nadal","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejphar.2026.178921_bib51","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrcardio.2014.28","article-title":"The inflammatory response in myocardial injury, repair, and remodelling","volume":"11","author":"Frangogiannis","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejphar.2026.178921_bib52","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib53","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2026.178921_bib54","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2026.178921_bib55","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2025.2332","article-title":"Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity: the HISTORI randomized clinical trial","author":"Ganeshalingam","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.ejphar.2026.178921_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-023-02096-9","article-title":"Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network","volume":"23","author":"Garc\u00eda-Vega","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2026.178921_bib57","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.ajkd.2008.04.012","article-title":"Prevalence and associations of coronary artery calcification in patients with stages 3 to 5 CKD without cardiovascular disease","volume":"52","author":"Garland","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2026.178921_bib58","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094824","article-title":"Kidney disease in diabetic patients: from pathophysiology to pharmacological aspects with a focus on therapeutic inertia","volume":"22","author":"Gembillo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178921_bib60","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","article-title":"Oxidative stress and diabetic complications","volume":"107","author":"Giacco","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2026.178921_bib61","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejim.2021.11.008","article-title":"Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: a treatment approach far beyond their glucose-lowering effect","volume":"96","author":"G\u00f3mez-Huelgas","year":"2022","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib62","first-page":"2003","article-title":"Oxidative stress, mitochondrial damage and neurodegenerative diseases","volume":"8","author":"Guo","year":"2013","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.ejphar.2026.178921_bib63","first-page":"455","article-title":"Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes","volume":"27","author":"Guzauskas","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.ejphar.2026.178921_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115235","article-title":"Therapeutic implications of targeting pyroptosis in Cardiac-related etiology of heart failure","volume":"204","author":"Habimana","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178921_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/life14060690","article-title":"Effect of GLP-1RA treatment on adhesion molecules and monocyte chemoattractant Protein-1 in diabetic patients with atherosclerosis","volume":"14","author":"Hachu\u0142a","year":"2024","journal-title":"Life"},{"key":"10.1016\/j.ejphar.2026.178921_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/ph16091190","volume":"16","author":"Hachu\u0142a","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2026.178921_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031854","article-title":"Impact of glucagon-like peptide 1 receptor agonists on biochemical markers of the initiation of atherosclerotic process","volume":"25","author":"Hachu\u0142a","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178921_bib68","article-title":"Semaglutide ameliorates pressure overload-induced cardiac hypertrophy by improving cardiac mitophagy to suppress the activation of NLRP3 inflammasome","volume":"14","author":"He","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2026.178921_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/antiox11101958","article-title":"Roles of oxidative stress and inflammation in vascular endothelial dysfunction-related disease","volume":"11","author":"Higashi","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.ejphar.2026.178921_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/cells12010088","article-title":"Oxidative stress and mitochondrial dysfunction in chronic kidney disease","volume":"12","author":"Ho","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2026.178921_bib71","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1111\/dom.14473","article-title":"Response to Dahl et al.: oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes","volume":"23","author":"Horowitz","year":"2021","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2026.178921_bib72","article-title":"Acute pancreatitis likely due to semaglutide","volume":"16","author":"Hughes","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.ejphar.2026.178921_bib73","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12933-025-02607-w","article-title":"The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)","volume":"24","author":"Hullon","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2026.178921_bib74","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12933-020-01106-4","article-title":"Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","volume":"19","author":"Husain","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2026.178921_bib75","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24108494","article-title":"Semaglutide has beneficial effects on non-alcoholic steatohepatitis in Ldlr-\/-.Leiden mice","volume":"24","author":"Inia","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178921_bib77","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.clnu.2024.12.004","article-title":"Beyond fat: does semaglutide affect lean mass?","volume":"44","author":"Jamialahmadi","year":"2025","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.ejphar.2026.178921_bib78","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib79","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.athplu.2022.05.004","article-title":"Semaglutide treatment attenuates vessel remodelling in ApoE-\/- mice following vascular injury and blood flow perturbation","volume":"49","author":"Jensen","year":"2022","journal-title":"Atheroscler Plus"},{"key":"10.1016\/j.ejphar.2026.178921_bib80","doi-asserted-by":"crossref","first-page":"F1105","DOI":"10.1152\/ajprenal.00285.2020","article-title":"Mitochondrial dysfunction and the AKI-to-CKD transition","volume":"319","author":"Jiang","year":"2020","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejphar.2026.178921_bib81","article-title":"Sustained effects of glucagon-like Peptide-1 (GLP-1) agonists on blood pressure in obesity and type 2 diabetes: a longitudinal case study","volume":"17","author":"Joseph","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.ejphar.2026.178921_bib82","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1111\/dom.14829","article-title":"Interconnection between cardiovascular, renal and metabolic disorders: a narrative review with a focus on Japan","volume":"24","author":"Kadowaki","year":"2022","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2026.178921_bib83","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.2337\/dc24-0491","article-title":"Effect of semaglutide on regression and progression of glycemia in people with overweight or obesity but without diabetes in the SELECT trial","volume":"47","author":"Kahn","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2026.178921_bib84","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1681\/ASN.2011010084","article-title":"Macrophages promote cyst growth in polycystic kidney disease","volume":"22","author":"Karihaloo","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2026.178921_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112293","article-title":"Endoplasmic reticulum stress related factor IRE1\u03b1 regulates TXNIP\/NLRP3-mediated pyroptosis in diabetic nephropathy","volume":"396","author":"Ke","year":"2020","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejphar.2026.178921_bib86","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1093\/eurheartj\/ehae564","article-title":"Semaglutide and blood pressure: an individual patient data meta-analysis","volume":"45","author":"Kennedy","year":"2024","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2026.178921_bib87","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41419-021-03452-x","article-title":"Characterization of ferroptosis in kidney tubular cell death under diabetic conditions","volume":"12","author":"Kim","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2026.178921_bib88","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib89","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2026.178921_bib90","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib91","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/CIRCULATIONAHA.123.067505","article-title":"Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial","volume":"149","author":"Kosiborod","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2026.178921_bib92","doi-asserted-by":"crossref","first-page":"Jc31","DOI":"10.7326\/J24-0008","article-title":"In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo","volume":"177","author":"Koutroumpakis","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib93","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1001\/jama.2025.14092","article-title":"Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction","volume":"334","author":"Kr\u00fcger","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2026.178921_bib94","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature14893","article-title":"The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy","volume":"524","author":"Lazarou","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.178921_bib95","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2337\/dc24-1533","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2026.178921_bib96","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-019-0871-8","article-title":"Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial","volume":"18","author":"Leiter","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2026.178921_bib97","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nri2156","article-title":"Getting to the site of inflammation: the leukocyte adhesion cascade updated","volume":"7","author":"Ley","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2026.178921_bib98","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2025.13476","article-title":"Semaglutide enhances PINK1\/Parkin-dependent mitophagy in hypoxia\/reoxygenation-induced cardiomyocyte injury","volume":"31","author":"Li","year":"2025","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejphar.2026.178921_bib99","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1097\/CM9.0000000000001772","article-title":"Molecular mechanism and therapeutic targeting of necrosis, apoptosis, pyroptosis, and autophagy in cardiovascular disease","volume":"134","author":"Li","year":"2021","journal-title":"Chin Med J (Engl)."},{"key":"10.1016\/j.ejphar.2026.178921_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117531","article-title":"Semaglutide attenuates excessive exercise-induced myocardial injury through inhibiting oxidative stress and inflammation in rats","volume":"250","author":"Li","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2026.178921_bib101","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2174\/1570159X23666240918103730","article-title":"Olanzapine-induced weight gain and glycolipid metabolism aberrations in first-episode and antipsychotic-na\u00efve schizophrenia patients: a longitudinal study","volume":"23","author":"Li","year":"2025","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ejphar.2026.178921_bib102","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.freeradbiomed.2020.10.323","article-title":"Inhibition of ferroptosis by up-regulating Nrf2 delayed the progression of diabetic nephropathy","volume":"162","author":"Li","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103129","article-title":"Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction","volume":"72","author":"Li","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejphar.2026.178921_bib104","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00592-023-02184-y","article-title":"GLP-1RAs inhibit the activation of the NLRP3 inflammasome signaling pathway to regulate mouse renal podocyte pyroptosis","volume":"61","author":"Li","year":"2024","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.ejphar.2026.178921_bib105","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.178921_bib106","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.178921_bib107","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.medj.2024.06.011","article-title":"Therapy for HFpEF: a step forward brings new hope for people with obesity and diabetes","volume":"5","author":"Lim","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.ejphar.2026.178921_bib108","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/bph.17327","article-title":"Semaglutide protects against diabetes-associated cardiac inflammation via Sirt3-dependent RKIP pathway","volume":"182","author":"Lin","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178921_bib109","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib110","article-title":"Semaglutide attenuates myocardial ischemia-reperfusion injury by inhibiting ferroptosis of cardiomyocytes via activation of PKC-S100A9 axis","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178921_bib111","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/ndt\/gfg414","article-title":"Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality","volume":"18","author":"London","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2026.178921_bib112","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.freeradbiomed.2024.01.015","article-title":"Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress","volume":"213","author":"Luna-Marco","year":"2024","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib113","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1038\/s41467-024-48970-2","article-title":"Semaglutide ameliorates cardiac remodeling in male mice by optimizing energy substrate utilization through the Creb5\/NR4a1 axis","volume":"15","author":"Ma","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2026.178921_bib114","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13098-022-00801-4","article-title":"The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal","volume":"14","author":"Malkin","year":"2022","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.ejphar.2026.178921_bib115","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/dom.14443","article-title":"Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis","volume":"23","author":"Mann","year":"2021","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2026.178921_bib116","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jacc.2024.05.065","article-title":"Effect of Semaglutide on Epicardial Adipose Tissue in Type 2 diabetes: insights from the STOP (Semaglutide Treatment effect on coronary atherosclerosis progression) randomized Trial","volume":"84","author":"Manubolu","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2026.178921_bib117","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12933-023-01937-x","article-title":"The cardio-renal-metabolic connection: a review of the evidence","volume":"22","author":"Marassi","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2026.178921_bib118","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib119","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jacbts.2024.07.006","article-title":"Semaglutide reduces cardiomyocyte size and cardiac mass in Lean and Obese mice","volume":"9","author":"Martens","year":"2024","journal-title":"JACC, Basic Transl. Sci."},{"key":"10.1016\/j.ejphar.2026.178921_bib120","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-8587(20)30343-0","article-title":"Guideline recommendations and the positioning of newer drugs in type 2 diabetes care","volume":"9","author":"Marx","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejphar.2026.178921_bib121","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.125.074545","article-title":"Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial","volume":"151","author":"Marx","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2026.178921_bib122","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2215\/CJN.01930408","article-title":"Accelerated atherosclerotic calcification and Monckeberg's sclerosis: a continuum of advanced vascular pathology in chronic kidney disease","volume":"3","author":"McCullough","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2026.178921_bib123","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/oby.23732","article-title":"Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: post hoc analyses of the STEP 1 randomized trial","volume":"31","author":"McGowan","year":"2023","journal-title":"Obesity"},{"key":"10.1016\/j.ejphar.2026.178921_bib124","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib125","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s10495-021-01663-3","article-title":"Release mechanisms of major DAMPs","volume":"26","author":"Murao","year":"2021","journal-title":"Apoptosis"},{"key":"10.1016\/j.ejphar.2026.178921_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20081386","article-title":"How mitochondria produce reactive oxygen species","volume":"417","author":"Murphy","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejphar.2026.178921_bib127","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like Peptide-1 receptor agonists and dipeptidyl Peptidase-4 inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2026.178921_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejphar.2026.178921_bib129","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2026.178921_bib130","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-Kidney-Metabolic health: a presidential advisory from the American heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2026.178921_bib131","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.trsl.2008.12.008","article-title":"Renin-angiotensin-aldosterone system-mediated redox effects in chronic kidney disease","volume":"153","author":"Nistala","year":"2009","journal-title":"Transl. Res."},{"key":"10.1016\/j.ejphar.2026.178921_bib132","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s10803-016-3013-0","article-title":"Planning skills in autism spectrum disorder across the lifespan: a meta-analysis and meta-regression","volume":"47","author":"Olde Dubbelink","year":"2017","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.ejphar.2026.178921_bib133","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2025.111583","article-title":"Semaglutide attenuates lipotoxicity-induced cardiac injury by inhibiting Slc27a2 expression","volume":"418","author":"Pan","year":"2025","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejphar.2026.178921_bib135","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s11010-023-04784-2","article-title":"Semaglutide ameliorates obesity-induced cardiac inflammation and oxidative stress mediated via reduction of neutrophil Cxcl2, S100a8, and S100a9 expression","volume":"479","author":"Pan","year":"2024","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ejphar.2026.178921_bib136","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.2147\/JIR.S391859","article-title":"Effects of semaglutide on cardiac protein expression and cardiac function of Obese mice","volume":"15","author":"Pan","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.ejphar.2026.178921_bib137","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7489795","article-title":"Association of glycemic indices (Hyperglycemia, glucose variability, and hypoglycemia) with oxidative stress and diabetic complications","volume":"2020","author":"Papachristoforou","year":"2020","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.ejphar.2026.178921_bib138","doi-asserted-by":"crossref","first-page":"H370","DOI":"10.1152\/ajpheart.00257.2024","article-title":"GLP-1RA therapy increases circulating vascular regenerative cell content in people living with type 2 diabetes","volume":"327","author":"Park","year":"2024","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2026.178921_bib139","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1749-6632.2012.06569.x","article-title":"The hypothalamic-pituitary-adrenal axis and sex hormones in chronic stress and obesity: pathophysiological and clinical aspects","volume":"1264","author":"Pasquali","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2026.178921_bib140","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib141","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacc.2024.04.022","article-title":"Semaglutide and NT-proBNP in obesity-related HFpEF: insights from the STEP-HFpEF program","volume":"84","author":"Petrie","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2026.178921_bib142","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(-\/-) and LDLr(-\/-) mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC, Basic Transl. Sci."},{"key":"10.1016\/j.ejphar.2026.178921_bib143","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1007\/s11606-020-06070-z","article-title":"Changes in mortality in top 10 Causes of Death from 2011 to 2018","volume":"36","author":"Rana","year":"2021","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib144","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11892-021-01446-9","article-title":"Adipose tissue inflammation and cardiovascular disease: an update","volume":"22","author":"Rana","year":"2022","journal-title":"Curr. Diabetes Rep."},{"key":"10.1016\/j.ejphar.2026.178921_bib145","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1582-4934.2005.tb00492.x","article-title":"Don't lose heart--therapeutic value of apoptosis prevention in the treatment of cardiovascular disease","volume":"9","author":"Reeve","year":"2005","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib146","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1359786806066040","article-title":"The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics","volume":"20","author":"Reynolds","year":"2006","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2026.178921_bib147","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2026.178921_bib148","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12933-023-01949-7","article-title":"Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis","volume":"22","author":"Rossing","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2026.178921_bib149","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/ki.1984.70","article-title":"Dialysis-associated ischemic heart disease: insights from coronary angiography","volume":"25","author":"Rostand","year":"1984","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2026.178921_bib150","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib151","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14292","article-title":"Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: a systematic review and meta-analysis","volume":"54","author":"Saglietto","year":"2024","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2026.178921_bib152","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejphar.2026.178921_bib153","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.gde.2004.04.012","article-title":"Pathophysiology and biochemistry of cardiovascular disease","volume":"14","author":"Scott","year":"2004","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.ejphar.2026.178921_bib154","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1093\/eurheartj\/ehae322","article-title":"Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials","volume":"45","author":"Shah","year":"2024","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2026.178921_bib155","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrneurol.2017.13","article-title":"The far-reaching scope of neuroinflammation after traumatic brain injury","volume":"13","author":"Simon","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejphar.2026.178921_bib156","doi-asserted-by":"crossref","first-page":"C812","DOI":"10.1152\/ajpcell.00246.2021","article-title":"Mitochondrial ion channels in cardiac function","volume":"321","author":"Singh","year":"2021","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejphar.2026.178921_bib157","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4196\/kjpp.2014.18.1.1","article-title":"Advanced glycation end products and diabetic complications","volume":"18","author":"Singh","year":"2014","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178921_bib158","doi-asserted-by":"crossref","first-page":"E664","DOI":"10.1210\/jc.2012-3855","article-title":"Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men","volume":"98","author":"Skov","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2026.178921_bib159","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuint.2019.04.010","article-title":"GLP-1: molecular mechanisms and outcomes of a complex signaling system","volume":"128","author":"Smith","year":"2019","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejphar.2026.178921_bib160","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/ejhf.2563","article-title":"Sex and central obesity in heart failure with preserved ejection fraction","volume":"24","author":"Sorimachi","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejphar.2026.178921_bib161","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7092151","article-title":"Vascular inflammation and oxidative stress: major triggers for cardiovascular disease","volume":"2019","author":"Steven","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejphar.2026.178921_bib162","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","article-title":"Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease","volume":"171","author":"Stockwell","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2026.178921_bib163","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/ATVBAHA.124.321850","article-title":"Semaglutide improves myocardial perfusion and performance in a large animal model of coronary artery disease","volume":"45","author":"Stone","year":"2025","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejphar.2026.178921_bib164","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/s41401-024-01448-9","article-title":"Semaglutide administration protects cardiomyocytes in db\/db mice via energetic improvement and mitochondrial quality control","volume":"46","author":"Tian","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2026.178921_bib165","article-title":"GLP-1 receptor agonists alleviate diabetic kidney injury via \u03b2-Klotho-Mediated ferroptosis inhibition","volume":"12","author":"Tian","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.ejphar.2026.178921_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2025.06.007","article-title":"Efficacy and safety of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction, type 2 diabetes and obesity: a real-world study","author":"Trenas","year":"2025","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib167","series-title":"ADQI Consensus on AKI Biomarkers and Cardiorenal Syndromes","first-page":"1","article-title":"Cardiorenal syndrome type 4: insights on clinical presentation and pathophysiology from the eleventh consensus conference of the acute dialysis quality initiative (ADQI)","author":"Tumlin","year":"2013"},{"key":"10.1016\/j.ejphar.2026.178921_bib168","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1113\/jphysiol.2003.049478","article-title":"Mitochondrial formation of reactive oxygen species","volume":"552","author":"Turrens","year":"2003","journal-title":"J Physiol."},{"key":"10.1016\/j.ejphar.2026.178921_bib169","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","article-title":"Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo","volume":"103","author":"Tuttle","year":"2023","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2026.178921_bib170","series-title":"Kidney Week 2025","article-title":"Mechanistic effects of semaglutide on kidney disease in type 2 diabetes: the REMODEL trial","author":"Tuttle","year":"2025"},{"key":"10.1016\/j.ejphar.2026.178921_bib171","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/dbi20-0049","article-title":"Cardiovascular effects of incretin-based therapies: integrating mechanisms with cardiovascular outcome trials","volume":"71","author":"Ussher","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2026.178921_bib172","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The global burden of cardiovascular diseases and risk: a compass for future health","volume":"80","author":"Vaduganathan","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2026.178921_bib173","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/dom.14700","article-title":"Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease","volume":"24","author":"Verma","year":"2022","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2026.178921_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101737","article-title":"Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials","volume":"55","author":"Verma","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ejphar.2026.178921_bib175","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jacc.2024.06.001","article-title":"Efficacy of semaglutide by sex in obesity-related heart failure with preserved ejection fraction: step-hfpef trials","volume":"84","author":"Verma","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2026.178921_bib176","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jacc.2024.08.028","article-title":"Inflammation in obesity-related HFpEF: the STEP-HFpEF program","volume":"84","author":"Verma","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2026.178921_bib177","article-title":"A bibliometric analysis of inflammatory bowel disease and COVID-19 researches","volume":"11","author":"Wang","year":"2023","journal-title":"Front. Public Health"},{"key":"10.1016\/j.ejphar.2026.178921_bib178","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41419-020-02777-3","article-title":"Pyroptosis and ferroptosis induced by mixed lineage kinase 3 (MLK3) signaling in cardiomyocytes are essential for myocardial fibrosis in response to pressure overload","volume":"11","author":"Wang","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2026.178921_bib179","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13098-025-01736-2","article-title":"Semaglutide and adenosine alleviate obesity-induced kidney injury, with observed modulation of the Txnip\/NLRP3 pathway","volume":"17","author":"Wang","year":"2025","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.ejphar.2026.178921_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173574","article-title":"Ferroptosis involves in renal tubular cell death in diabetic nephropathy","volume":"888","author":"Wang","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178921_bib181","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3945\/ajcn.2010.29885","article-title":"Specific metabolic rates of major organs and tissues across adulthood: evaluation by mechanistic model of resting energy expenditure","volume":"92","author":"Wang","year":"2010","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.ejphar.2026.178921_bib182","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib183","doi-asserted-by":"crossref","first-page":"A16","DOI":"10.1210\/jendso\/bvab048.030","article-title":"Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study","volume":"5","author":"Wilding","year":"2021","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.ejphar.2026.178921_bib184","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacbts.2023.05.012","article-title":"The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF","volume":"8","author":"Withaar","year":"2023","journal-title":"JACC, Basic Transl. Sci."},{"key":"10.1016\/j.ejphar.2026.178921_bib185","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202501605R","article-title":"GLP-1RA semaglutide delays the progression of ADPKD through regulation of glycolysis, Mitochondria function and ketosis","volume":"39","author":"Wu","year":"2025","journal-title":"Faseb j."},{"key":"10.1016\/j.ejphar.2026.178921_bib186","doi-asserted-by":"crossref","first-page":"6637","DOI":"10.1038\/s41467-021-26987-1","article-title":"The APPL1-Rab5 axis restricts NLRP3 inflammasome activation through early endosomal-dependent mitophagy in macrophages","volume":"12","author":"Wu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2026.178921_bib187","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijcard.2022.05.025","article-title":"PINK1\/Parkin-mediated mitophagy in cardiovascular disease: from pathogenesis to novel therapy","volume":"361","author":"Wu","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejphar.2026.178921_bib188","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.ajpath.2023.06.013","article-title":"Current advances of mitochondrial dysfunction and cardiovascular disease and promising therapeutic strategies","volume":"193","author":"Xia","year":"2023","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2026.178921_bib189","first-page":"9908","article-title":"Clinical effectiveness of semaglutide on weight loss, body composition, and muscle strength in Chinese adults","volume":"27","author":"Xiang","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2026.178921_bib190","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41392-025-02253-4","article-title":"Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances","volume":"10","author":"Xu","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2026.178921_bib191","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s12020-024-03823-2","article-title":"Semaglutide attenuates pathological electrophysiological remodeling in diabetic cardiomyopathy via restoring Cx43 expression","volume":"84","author":"Yan","year":"2024","journal-title":"Endocrine"},{"key":"10.1016\/j.ejphar.2026.178921_bib192","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.2147\/DDDT.S495659","article-title":"Semaglutide reduces cardiomyocyte damage caused by high-fat through HSDL2","volume":"18","author":"Yang","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejphar.2026.178921_bib193","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1161\/HYPERTENSIONAHA.116.07876","article-title":"Regional fat distribution and blood pressure level and variability: the Dallas heart study","volume":"68","author":"Yano","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2026.178921_bib194","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"Bmj"},{"key":"10.1016\/j.ejphar.2026.178921_bib195","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/DDDT.S195412","article-title":"Emodin alleviates myocardial ischemia\/reperfusion injury by inhibiting gasdermin D-mediated pyroptosis in cardiomyocytes","volume":"13","author":"Ye","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejphar.2026.178921_bib196","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2016.07.158","article-title":"GW27-e1177 Semaglutide protects cardiac microvascular endothelial cells against hypoxia\/reoxygenation injury through the suppression of the SR-Ca2+-XO-ROS axis via activation of the GLP-1R\/PI3K\/Akt\/Survivin pathways","volume":"68","author":"Ying","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2026.178921_bib197","first-page":"1208","article-title":"Cardiorenal syndrome and heart failure-challenges and opportunities","volume":"35","author":"Yogasundaram","year":"2019","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ejphar.2026.178921_bib198","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature01158","article-title":"The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease","volume":"420","author":"Youssef","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.178921_bib199","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1007\/s13300-020-00922-x","article-title":"Pharmacogenomic studies of current antidiabetic agents and potential new drug targets for precision medicine of diabetes","volume":"11","author":"Zeng","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ejphar.2026.178921_bib200","doi-asserted-by":"crossref","first-page":"853","DOI":"10.24976\/Discov.Med.202335178.80","article-title":"Semaglutide pretreatment induces cardiac autophagy to reduce myocardial injury in septic mice","volume":"35","author":"Zhang","year":"2023","journal-title":"Discov. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib201","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000345436","article-title":"Acute blood glucose fluctuation induces myocardial apoptosis through oxidative stress and nuclear factor-\u0138B activation","volume":"124","author":"Zhang","year":"2013","journal-title":"Cardiology"},{"key":"10.1016\/j.ejphar.2026.178921_bib202","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109646","article-title":"Extracellular matrix, integrins, and focal adhesion signaling in polycystic kidney disease","volume":"72","author":"Zhang","year":"2020","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejphar.2026.178921_bib203","doi-asserted-by":"crossref","DOI":"10.1111\/dom.16621","article-title":"Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: pooled post hoc analysis of SUSTAIN 6 and PIONEER 6","author":"Zhou","year":"2025","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2026.178921_bib204","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000517723","article-title":"Targeting ferroptosis attenuates interstitial inflammation and kidney fibrosis","volume":"8","author":"Zhou","year":"2022","journal-title":"Kidney Dis."},{"key":"10.1016\/j.ejphar.2026.178921_bib205","doi-asserted-by":"crossref","first-page":"Jc122","DOI":"10.7326\/ANNALS-24-02457-JC","article-title":"In adults with BMI \u226527 kg\/m(2) and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA(1c) level","volume":"177","author":"Zhu","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejphar.2026.178921_bib206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2023.01.049","article-title":"Semaglutide inhibits ischemia\/reperfusion-induced cardiomyocyte apoptosis through activating PKG\/PKC\u03b5\/ERK1\/2 pathway","volume":"647","author":"Zhu","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2026.178921_bib207","article-title":"Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice","volume":"14","author":"Zhu","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejphar.2026.178921_bib208","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1152\/physrev.00026.2013","article-title":"Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release","volume":"94","author":"Zorov","year":"2014","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejphar.2026.178921_bib209","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-018-0691-2","article-title":"Bone markers and cardiovascular risk in type 2 diabetes patients","volume":"17","author":"Zwakenberg","year":"2018","journal-title":"Cardiovasc. Diabetol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926004036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926004036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T23:38:23Z","timestamp":1783208303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926004036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":209,"alternative-id":["S0014299926004036"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178921","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insights into semaglutide cardiovascular research: Mechanisms, trials, and frontiers","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178921"}}